The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer.

ABSTRACT: The success of the PROfound, IPATential150, and TheraP trials promoted the transition from sequential treatment to therapeutic targets (TTs)-guided precision treatment in metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to evaluate the prevalence and prognostic value of TTs from these three trials. All included Chinese mCRPC patients underwent circulating tumor DNA (ctDNA) sequencing, PTEN status assessment, and dual-tracer [⁶⁸ Ga-prostate-specific membrane antigen (PSMA) and ¹⁸ F-fluorodexyglucose (FDG)] positron emission tomography/computed tomography (PET/CT). Previous treatment with cabazitaxel, Lu-PSMA or olaparib was unallowed. Patients with known significant sarcomatoid or spindle cell or neuroendocrine small cell compone

SUBMITTER: Pan J 

PROVIDER: S-EPMC9718110 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature